Thierry Gil

9.0k total citations · 2 hit papers
94 papers, 3.5k citations indexed

About

Thierry Gil is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Thierry Gil has authored 94 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 19 papers in Surgery. Recurrent topics in Thierry Gil's work include Prostate Cancer Treatment and Research (25 papers), Radiopharmaceutical Chemistry and Applications (17 papers) and Cancer Treatment and Pharmacology (17 papers). Thierry Gil is often cited by papers focused on Prostate Cancer Treatment and Research (25 papers), Radiopharmaceutical Chemistry and Applications (17 papers) and Cancer Treatment and Pharmacology (17 papers). Thierry Gil collaborates with scholars based in Belgium, United States and France. Thierry Gil's co-authors include Laurence Collette, Cora N. Sternberg, Dionisio González, René‐Olivier Mirimanoff, Jacques Bernier, J.B. Dubois, Guy Storme, M. Piérart, M. Bolla and Abraham Kuten and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thierry Gil

92 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1997 1.2k citations Cora N. Sternberg, Thierry Gil et al. profile →
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

2011 523 citations Thierry Gil, Sandrine Marréaud et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thierry Gil Belgium	22	2.1k	1.1k	841	668	453	94	3.5k
Junji Yonese Japan	29	1.9k 0.9×	997 0.9×	790 0.9×	701 1.0×	422 0.9×	207	2.8k
D. De Raucourt France	22	1.9k 0.9×	2.2k 1.9×	1.9k 2.2×	787 1.2×	306 0.7×	55	4.4k
Wei‐Xiang Qi China	24	940 0.4×	1.1k 1.0×	391 0.5×	426 0.6×	227 0.5×	109	2.1k
Brigitte Laguerre France	25	1.8k 0.8×	972 0.8×	507 0.6×	919 1.4×	659 1.5×	152	2.6k
Ranee Mehra United States	38	2.3k 1.1×	4.1k 3.5×	1.4k 1.6×	1.5k 2.2×	746 1.6×	194	6.5k
Éveline Boucher France	32	1.2k 0.6×	1.3k 1.1×	1.1k 1.4×	333 0.5×	428 0.9×	118	3.7k
Ivan Borbath Belgium	31	1.4k 0.7×	4.7k 4.1×	1.5k 1.8×	635 1.0×	740 1.6×	155	6.3k
Lipika Goyal United States	31	1.4k 0.6×	2.5k 2.2×	2.3k 2.7×	1.3k 1.9×	854 1.9×	185	5.1k
Roger Ove United States	11	1.7k 0.8×	2.0k 1.7×	1.1k 1.3×	978 1.5×	422 0.9×	36	4.1k
Lisa Sengeløv Denmark	19	1.1k 0.5×	1.4k 1.3×	2.1k 2.5×	581 0.9×	417 0.9×	45	3.5k

Countries citing papers authored by Thierry Gil

Since Specialization

Citations

This map shows the geographic impact of Thierry Gil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Gil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Gil more than expected).

Fields of papers citing papers by Thierry Gil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Gil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Gil. The network helps show where Thierry Gil may publish in the future.

Co-authorship network of co-authors of Thierry Gil

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Gil. A scholar is included among the top collaborators of Thierry Gil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Gil. Thierry Gil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bernard, Brandon, Philippe Barthélémy, Marianne Paesmans, et al.. (2021). Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 199–207. 7 indexed citations

Chanzá, Nieves Martínez, Philippe Barthélémy, Thierry Gil, et al.. (2021). Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). BMC Cancer. 21(1). 1292–1292. 12 indexed citations

Artigas, Carlos, et al.. (2019). Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Annals of Nuclear Medicine. 33(12). 945–954. 40 indexed citations

Touati, Nathan, Patrick Schöffski, Saskia Litière, et al.. (2017). EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy. Annals of Oncology. 28. v528–v528. 1 indexed citations

Aftimos, Philippe, Lieveke Ameye, Christiane Jungels, et al.. (2016). Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. European Journal of Cancer. 60(29). 117–124. 20 indexed citations

Benson, Charlotte, Isabelle Ray‐Coquard, Stefan Sleijfer, et al.. (2016). Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecologic Oncology. 142(1). 89–94. 44 indexed citations

Tombal, Bertrand, Anja Desomer, Roland van Velthoven, et al.. (2014). National practice guideline on the treatment of localised prostate cancer. 2 indexed citations

Azambuja, Evandro de, Dimitrios Zardavas, Marc Lemort, et al.. (2013). Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of Oncology. 24(12). 2985–2989. 21 indexed citations

Schöffski, Patrick, Jorge A. García, Walter M. Stadler, et al.. (2010). A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. British Journal of Urology. 108(5). 679–686. 58 indexed citations

10.

Rossari, José Roberto Freitas, Tushar Vora, & Thierry Gil. (2010). Advances in penile cancer management. Current Opinion in Oncology. 22(3). 226–235. 9 indexed citations

11.

Sternberg, Cora N., Herlinde Dumez, Hendrik Van Poppel, et al.. (2009). Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of Oncology. 20(7). 1264–1269. 94 indexed citations

12.

Awada, Ahmad, Martine Piccart, Suzanne F. Jones, et al.. (2008). Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemotherapy and Pharmacology. 63(3). 417–425. 20 indexed citations

13.

Widakowich, C., Evandro de Azambuja, Thierry Gil, et al.. (2007). Molecular targeted therapies in breast cancer: Where are we now?. The International Journal of Biochemistry & Cell Biology. 39(7-8). 1375–1387. 29 indexed citations

14.

Kasper, Bernd, Thierry Gil, Véronique D’Hondt, M Gebhart, & Ahmad Awada. (2006). Novel treatment strategies for soft tissue sarcoma. Critical Reviews in Oncology/Hematology. 62(1). 9–15. 25 indexed citations

15.

Awada, Ahmad, Alain Hendlisz, Thierry Gil, et al.. (2004). A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors. European Journal of Cancer. 114. 4 indexed citations

16.

Awada, Ahmad, Thierry Gil, François Salès, et al.. (2004). Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 15(5). 499–502. 12 indexed citations

17.

Awada, Ahmad, Dominique de Valeriola, Alain Hendlisz, et al.. (2001). Phase I clinical and pharmacology study of the novel epothilone analog BMS-247550 given weekly in patients advanced solid tumors. Clinical Cancer Research. 3810. 6 indexed citations

18.

Oudard, Stéphane, Armelle Caty, Yves Humblet, et al.. (2001). Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Annals of Oncology. 12(6). 847–852. 39 indexed citations

19.

Awada, Ahmad, Pierre Bourgeois, Nathalie Cornez, et al.. (1999). A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors. Clinical Cancer Research. 3833. 1 indexed citations

20.

Kerger, Joseph, et al.. (1993). Etoposide oral administré de manière prolongé: un traitement partiellement non cross-résistant avec les dérivés Taxanes dans le cancer de l’ovaire. Bulletin du Cancer. 80(6). 522. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact